Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that Dr. Ken Weingardt, CEO of Audacious Digital Health, will be serving as senior clinical technology advisor. Weingardt is a clinical psychologist and has served as senior clinical director at Pear Therapeutics. Specifically, Weingardt will work with MINDCURE’s iSTRYM, the company’s digital therapeutics technology (“DTx”) platform, through near-term commercial deployment. iSTRYM is on schedule for MVP deployment in the third quarter of 2021, with commercial deployment slated for first quarter 2022. Weingardt , who most recently served as the director of clinical programs at Woebot Health, has two decades of experience focused on technology and behavioral health. iSTRYM is MINDCURE’s proprietary, first-of-its-kind software application that optimizes the healing journey for both patients and clinicians before, during, and after therapy sessions. The platform offers therapists global, evidence-backed treatment protocols, as well as in-session psychedelic-informed tools. In addition, the application features customizable dashboards, integration plans, insights into patient journeys and real-time assessments for personalized client care.
“Adding Ken to our team is a hallmark moment,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “We are in the early days of this fast-growing psychedelics market and are proud that Ken chose to work with MINDCURE. I’m honored and excited to show what we will achieve together. I believe that vision, teamwork, and speed of execution are the keys of every disruptive business that delivers on its strategy and drives results for its customers and its investors.”
To view the full press release, visit https://ibn.fm/WqbPf
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php